
MRMD.CN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MRMD.CN and 80,000+ other tickers.
See exactly how MRMD.CN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MRMD.CN and 80,000+ other tickers.
MariMed Inc. is a key player in the cannabis industry, involved in the cultivation, production, and distribution of both medicinal and adult-use cannabis products across the United States and internationally. The company's diverse brand portfolio includes Nature's Heritage for cannabis genetics, flowers, and concentrates, while Kalm Fusion offers cannabis-infused chewable tablets and powdered drink mixes. Its edibles segment features natural fruit chews under the Betty's Eddies brand and a variety of baked goods like brownies and cookies from Bubby's Baked. Additionally, MariMed develops…

NORWOOD, Mass. , July 15, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. ("MariMed" or the "Company") (CSE: MRMD) (OTCQB: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its second quarter 2026 financial results on August 12, 2026 after the markets close.

NORWOOD, Mass. , May 13, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. ("MariMed" or the "Company") (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2026.